Scott Dreyer - Collegium Pharmaceutical Executive Vice President Chief Commercial Officer
| COLL Stock | USD 29.96 0.45 1.48% |
President
Mr. Scott Dreyer is Executive Vice President and Chief Commercial Officer of the company. Mr. Dreyer has served as our Executive Vice President and Chief Commercial Officer since August 2018, and joined us in January 2018 as Senior Vice President, Sales, Marketing and Training. Prior to joining us, Mr. Dreyer served as the Senior Vice President, Sales, Marketing and Commercial Operations at The Medicines Company, a biopharmaceutical company, from September 2016 to December 2017 Vice President and Chief Marketing Officer US at Biogen from June 2014 to September 2016 and Vice President, Business Development at Publicis Touchpoint Solutions, a healthcare commercialization company, from October 2013 to June 2014. Mr. Dreyer began his career in the pharmaceutical industry at Merck Co., where he held roles of increasing responsibility from 1994 to 2013, including Vice President of Hospital and Oncology Sales from 2011 to 2012, and Vice President of Primary Care Sales from 2012 until 2013 since 2018.
| Age | 52 |
| Tenure | 6 years |
| Address | 100 Technology Center Drive, Stoughton, MA, United States, 02072 |
| Phone | 781 713 3699 |
| Web | https://www.collegiumpharma.com |
Latest Insider Transactions
Dreyer holds a B.S. in Biology from Messiah College in 1994.Scott Dreyer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Scott Dreyer against Collegium Pharmaceutical stock is an integral part of due diligence when investing in Collegium Pharmaceutical. Scott Dreyer insider activity provides valuable insight into whether Collegium Pharmaceutical is net buyers or sellers over its current business cycle. Note, Collegium Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Collegium Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Scott Dreyer over six months ago Disposition of 23791 shares by Scott Dreyer of Collegium Pharmaceutical at 24.03 subject to Rule 16b-3 |
Collegium Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0968 % which means that it generated a profit of $0.0968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4289 %, meaning that it created $0.4289 on every $100 dollars invested by stockholders. Collegium Pharmaceutical's management efficiency ratios could be used to measure how well Collegium Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to 0.09 this year. Return On Capital Employed is expected to rise to 0.26 this year. At this time, Collegium Pharmaceutical's Fixed Asset Turnover is quite stable compared to the past year. Return On Assets is expected to rise to 0.04 this year, although the value of Other Assets will most likely fall to about 21.1 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Robert Davis | Intracellular Th | 73 | |
| Ganadhish Kamat | Dr Reddys Laboratories | 57 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| Mauricio Caballero | Procaps Group SA | 47 | |
| John Condon | Intracellular Th | N/A | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| William PPool | Prestige Brand Holdings | 59 | |
| David Gaffin | Alkermes Plc | 52 | |
| Samson Li | Phibro Animal Health | 52 | |
| John Bardi | Intracellular Th | N/A | |
| Juan Sanchez | Intracellular Th | 53 | |
| Kurt Knab | Evolus Inc | N/A | |
| Lisa Escudero | Phibro Animal Health | 62 | |
| Michael Landine | Alkermes Plc | 70 | |
| Crystal Muilenburg | Evolus Inc | 44 | |
| Rob Aukerman | Phibro Animal Health | 66 | |
| Jonathan Bendheim | Phibro Animal Health | 48 | |
| Luis Aragon | Procaps Group SA | 60 | |
| Mark Neumann | Intracellular Th | 61 | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Marcela Pagano | Procaps Group SA | 57 | |
Management Performance
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0968 |
Collegium Pharmaceutical Leadership Team
Elected by the shareholders, the Collegium Pharmaceutical's board of directors comprises two types of representatives: Collegium Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Collegium. The board's role is to monitor Collegium Pharmaceutical's management team and ensure that shareholders' interests are well served. Collegium Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Collegium Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bart Dunn, Executive Development | ||
| Scott Dreyer, Executive Vice President Chief Commercial Officer | ||
| Scott Sudduth, Head Operations | ||
| Christopher MD, Vice Relations | ||
| Shirley JD, General VP | ||
| RPh Pharm, Chairman, CoFounder | ||
| Marlo Manning, Head HR | ||
| Joseph Ciaffoni, COO, Executive Vice President | ||
| Colleen Tupper, Executive CFO | ||
| Alex Dasalla, Head Relations | ||
| Richard MD, Ex Officer | ||
| MD FAAFP, Executive Officer | ||
| Vikram Karnani, President CEO | ||
| Shirley Kuhlmann, Executive Vice President General Counsel, Secretary |
Collegium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Collegium Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0968 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 1.72 B | ||||
| Shares Outstanding | 32.25 M | ||||
| Shares Owned By Insiders | 1.64 % | ||||
| Shares Owned By Institutions | 98.36 % | ||||
| Number Of Shares Shorted | 6.21 M | ||||
| Price To Earning | 28.80 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.